Preclinical Efficacy of Cabazitaxel Loaded Poly(2-alkyl cyanoacrylate) Nanoparticle Variants

References

• Youn YS, Bae YH. Perspectives on the past, present, and future of cancer nanomedicine. Adv Drug Del Rev. 2018;130:3–11. doi:10.1016/j.addr.2018.05.008
   PubMed Web of Science ®Google Scholar
• van der Meel R, Sulheim E, Shi Y, Kiessling F, Mulder WJM, Lammers T. Smart cancer nanomedicine. Nat Nanotechnol. 2019;14(11):1007–1017. doi:10.1038/s41565-019-0567-y
   PubMed Web of Science ®Google Scholar
• Nam J, Son S, Park KS, Zou W, Shea LD, Moon JJ. Cancer nanomedicine for combination cancer immunotherapy. Nat Rev Mater. 2019;4(6):398–414. doi:10.1038/s41578-019-0108-1
   Web of Science ®Google Scholar
• Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20–37. doi:10.1038/nrc.2016.108
   PubMed Web of Science ®Google Scholar
• Gagliardi A, Giuliano E, Venkateswararao E, et al. Biodegradable polymeric nanoparticles for drug delivery to solid tumors. Front Pharmacol. 2021;12:601626. doi:10.3389/fphar.2021.601626
   PubMed Web of Science ®Google Scholar
• Li S, Feng X, Wang J, et al. Polymer nanoparticles as adjuvants in cancer immunotherapy. Nano Res. 2018;11(11):5769–5786. doi:10.1007/s12274-018-2124-7
   Web of Science ®Google Scholar
• Merle P, Camus P, Abergel A, et al. Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma. ESMO open. 2017;2(4):e000238. doi:10.1136/esmoopen-2017-000238
   PubMed Web of Science ®Google Scholar
• Hyldbakk A, Mørch Y, Snipstad S, et al. Identification of novel cyanoacrylate monomers for use in nanoparticle drug delivery systems prepared by miniemulsion polymerisation–A multistep screening approach. Int J Pharm X. 2022;4:100124. doi:10.1016/j.ijpx.2022.100124
   PubMedGoogle Scholar
• Sulheim E, Iversen T-G, To Nakstad V, et al. Cytotoxicity of poly (alkyl cyanoacrylate) nanoparticles. Int J Mol Sci. 2017;18(11):2454. doi:10.3390/ijms18112454
   PubMed Web of Science ®Google Scholar
• Fusser M, Øverbye A, Pandya AD, et al. Cabazitaxel-loaded Poly (2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft. J Control Release. 2019;293:183–192. doi:10.1016/j.jconrel.2018.11.029
   PubMed Web of Science ®Google Scholar
• Szwed M, Sønstevold T, Øverbye A, et al. Small variations in nanoparticle structure dictate differential cellular stress responses and mode of cell death. Nanotoxicology. 2019;13(6):761–782. doi:10.1080/17435390.2019.1576238
   PubMed Web of Science ®Google Scholar
• Øverbye A, Torgersen ML, Sønstevold T, et al. Cabazitaxel-loaded poly (alkyl cyanoacrylate) nanoparticles: toxicity and changes in the proteome of breast, colon and prostate cancer cells. Nanotoxicology. 2021;15(7):865–884. doi:10.1080/17435390.2021.1924888
   PubMed Web of Science ®Google Scholar
• Hyldbakk A, Fleten KG, Snipstad S, et al. Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models. Nanomed Nanotechnol Biol Med. 2023;48:102656. doi:10.1016/j.nano.2023.102656
   PubMed Web of Science ®Google Scholar
• Abidi A. Cabazitaxel: a novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects. J Pharmacol Pharmacother. 2013;4(4):230–237. doi:10.4103/0976-500X.119704
   PubMedGoogle Scholar
• Huober J, Janni W, Untch M, et al. 168P Long-term survival of a randomised, open-label, Phase II study comparing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Ann Oncol. 2022;33:S615.
   Web of Science ®Google Scholar
• Bahl A, Wilson W, Ball J, et al. Concept: a randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer. Breast. 2022;66:69–76. doi:10.1016/j.breast.2022.09.005
   PubMed Web of Science ®Google Scholar
• Pourmadadi M, Ghaemi A, Shaghaghi M, Rahdar A, Pandey S. Cabazitaxel-nano delivery systems as a cutting-edge for cancer therapy. J Drug Deliv Sci Technol. 2023;82:104338. doi:10.1016/j.jddst.2023.104338
   Web of Science ®Google Scholar
• Almansour NM. Triple-negative breast cancer: a brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence. Front Mol Biosci. 2022;9:32. doi:10.3389/fmolb.2022.836417
   Web of Science ®Google Scholar
• Bahrami B, Mohammadnia-Afrouzi M, Bakhshaei P, et al. Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy. Tumor Biol. 2015;36(8):5727–5742. doi:10.1007/s13277-015-3706-6
   PubMedGoogle Scholar
• Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–821. doi:10.1038/s41423-020-0488-6
   PubMed Web of Science ®Google Scholar
• Lee NK, Kim S-N, Park CG. Immune cell targeting nanoparticles: a review. Biomater Res. 2021;25(1):1–11. doi:10.1186/s40824-021-00246-2
   PubMedGoogle Scholar
• Sun W, Yang J, Hou M, et al. A nano “Immune‐Guide” recruiting lymphocytes and modulating the ratio of macrophages from different origins to enhance cancer immunotherapy. Adv Funct Mater. 2021;31(23):2009116. doi:10.1002/adfm.202009116
   Web of Science ®Google Scholar
• Reichel D, Tripathi M, Perez JM. Biological effects of nanoparticles on macrophage polarization in the tumor microenvironment. Nanotheranostics. 2019;3(1):66. doi:10.7150/ntno.30052
   PubMedGoogle Scholar
• Cao X, Li B, Chen J, et al. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer. J Immunother Cancer. 2021;9(3):e002022. doi:10.1136/jitc-2020-002022
   PubMed Web of Science ®Google Scholar
• Klymchenko AS, Roger E, Anton N, et al. Highly lipophilic fluorescent dyes in nano-emulsions: towards bright non-leaking nano-droplets. RSC Adv. 2012;2(31):11876–11886. doi:10.1039/c2ra21544f
   PubMed Web of Science ®Google Scholar
• Michelini S, Barbero F, Prinelli A, et al. Gold nanoparticles (AuNPs) impair LPS-driven immune responses by promoting a tolerogenic-like dendritic cell phenotype with altered endosomal structures. Nanoscale. 2021;13(16):7648–7666. doi:10.1039/D0NR09153G
   PubMed Web of Science ®Google Scholar
• Schwarz H, Gornicec J, Neuper T, et al. Biological activity of masked endotoxin. Sci Rep. 2017;7(1):1–11. doi:10.1038/srep44750
   PubMedGoogle Scholar
• Moghimi SM, Simberg D. Critical issues and pitfalls in serum and plasma handling for complement analysis in nanomedicine and bionanotechnology. Nano Today. 2022;44:101479. doi:10.1016/j.nantod.2022.101479
   Web of Science ®Google Scholar
• Wibroe PP, Anselmo AC, Nilsson PH, et al. Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes. Nat Nanotechnol. 2017;12(6):589–594. doi:10.1038/nnano.2017.47
   PubMed Web of Science ®Google Scholar
• L-P W, Ficker M, Christensen JB, Simberg D, Trohopoulos PN, Moghimi SM. Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking. Nat Commun. 2021;12(1):4858. doi:10.1038/s41467-021-24960-6
   PubMed Web of Science ®Google Scholar
• Valsalakumari R, Yadava SK, Szwed M, et al. Mechanism of cellular uptake and cytotoxicity of paclitaxel loaded lipid nanocapsules in breast cancer cells. Int J Pharm. 2021;597:120217. doi:10.1016/j.ijpharm.2021.120217
   PubMed Web of Science ®Google Scholar
• Bergamaschi A, Hjortland GO, Triulzi T, et al. Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol. 2009;3(5–6):469–482. doi:10.1016/j.molonc.2009.07.003
   PubMed Web of Science ®Google Scholar
• Marangoni E, Vincent-Salomon A, Auger N, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 2007;13(13):3989–3998. doi:10.1158/1078-0432.CCR-07-0078
   PubMed Web of Science ®Google Scholar
• Schwarz H, Schmittner M, Duschl A, Horejs-Hoeck J, Li L. Residual endotoxin contaminations in recombinant proteins are sufficient to activate human CD1c+ dendritic cells. PLoS One. 2014;9(12):e113840. doi:10.1371/journal.pone.0113840
   PubMed Web of Science ®Google Scholar
• Gorbet MB, Sefton MV. Endotoxin: the uninvited guest. Biomaterials. 2005;26(34):6811–6817. doi:10.1016/j.biomaterials.2005.04.063
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Dadswell CM, Savay S, Alving CR, Szebeni J. Causative factors behind poloxamer 188 (Pluronic F68, Flocor™)-induced complement activation in human sera: a protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. Biochim Biophys Acta Mol Basis Dis. 2004;1689(2):103–113. doi:10.1016/j.bbadis.2004.02.005
   PubMed Web of Science ®Google Scholar
• Valencia PM, Hanewich-Hollatz MH, Gao W, et al. Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials. 2011;32(26):6226–6233. doi:10.1016/j.biomaterials.2011.04.078
   PubMed Web of Science ®Google Scholar
• Liu Q, Yang C, Wang S, et al. Wnt5a-induced M2 polarization of tumor-associated macrophages via IL-10 promotes colorectal cancer progression. Cell Commun Signal. 2020;18(1):51. doi:10.1186/s12964-020-00557-2
   PubMed Web of Science ®Google Scholar
• Yang C, He L, He P, et al. Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway. Med Oncol. 2015;32(2):14. doi:10.1007/s12032-014-0352-6
   Web of Science ®Google Scholar
• Steggerda SM, Bennett MK, Chen J, et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J Immunother Cancer. 2017;5(1):1–18. doi:10.1186/s40425-017-0308-4
   PubMedGoogle Scholar
• Menjivar RE, Nwosu ZC, Du W, et al. Arginase 1 is a key driver of immune suppression in pancreatic cancer. Elife. 2023;12:e80721. doi:10.7554/eLife.80721
   PubMedGoogle Scholar
• Fumoleau P, Trigo JM, Isambert N, Sémiond D, Gupta S, Campone M. Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours. BMC Cancer. 2013;13:1–9. doi:10.1186/1471-2407-13-460
   PubMed Web of Science ®Google Scholar